

*The Reply:*

We read with interest the letter from Dr. Ziegelstein in response to our publication in the Journal.<sup>1</sup> We must reiterate that we sought to investigate the relation between aspirin dose and aspirin resistance as measured by a point-of-care assay only. The title of our article just reflects what we found and has no suggestions for any actions needed for this observation. It is beyond the scope of the present work to examine the mechanistic explanation for this phenomenon. We concur with the position paper of the International Society on Thrombosis and Haemostasis that we need more studies to link the laboratory findings to adverse clinical events and the benefits of altering antiplatelet therapy based on such a finding.<sup>2</sup> With currently available information, modification of existing antiplatelet therapy for reducing the occurrence of aspirin resistance should be discouraged.

Wai-Hong Chen, MBBS, FACC  
Pui-Yin Lee, MBBS  
*Division of Cardiology  
Department of Medicine  
The University of Hong Kong  
Queen Mary Hospital  
Hong Kong, China*

doi:10.1016/j.amjmed.2005.10.053

**References**

1. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *Am J Med* 2005;118:723-727.
2. Michelson AD, Cattaneo M, Eikelboom JW, et al on behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. *J Thromb Haemost* 2005;3:1309-1311.